Abstract
Rheumatoid arthritis (RA) is a clinically regular systemic immune disease caused by multiple genes or other factors. In a long time, scientists have taken many treasures to treat this disease. Due to the multiplicity of rheumatoid arthritis and the adverse effects of traditional drugs for the treatment of rheumatoid arthritis, scientists are actively trying to develop new technical methods, such as combining nanotechnology with traditional drugs to improve drug delivery efficiency and reduce the adverse reactions caused by traditional medicine. There are some typical pathological features in the development of rheumatoid arthritis. This review will focus on the theme of "Designing different nanomedicines based on pathological features" and divide the review into three parts: passive targeting, active targeting, stimulus-responsive targeting, In this review, the current nanomedicines for the treatment of rheumatoid arthritis are classified and summarized, with the prospection of future development of the technology at last.
Publisher
Darcy & Roy Press Co. Ltd.
Reference75 articles.
1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356-361.
2. Deng LH, Gong Y, Huang XL, et al. Advances in exocrine in the pathogenesis of rheumatoid arthritis, Journal of the Chinese Academy of Medical Sciences ,2019;41(4):556-561.
3. Elisa C, Alessandra M. An update on research advances in rheumatoid arthritis: from clinic to basic science, The Journal of Laboratory and Precision Medicine,2018;3:54-54.
4. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet, 2016; 388(20): 23-38.
5. Pham CT. Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(6):607-619.